AI Article Synopsis
- A 2-year randomized double-blind trial tested isaxonine in 20 boys aged 5 1/2-10 with Duchenne muscular dystrophy.
- The study measured walking times, motor ability, muscle strength, and myometry, but found no significant effect of the drug on disease progression.
- Results indicated that muscle force measurements were more statistically powerful than function assessments, suggesting future trials should focus more on muscle strength indicators.
Article Abstract
A randomized double-blind therapeutic trial of isaxonine was completed over a 2-year period for 20 ambulant boys with Duchenne muscular dystrophy aged 5 1/2-10 years. The effect of the drug was monitored by measurement of walking times over 28 and 150 ft, motor ability score, MRC score based on 32 muscle groups, and myometry of 7 muscle groups. The drug had no significant effect on the progression of the disease. The trial had statistical power comparable to previous larger-scale multicenter trials. This reflected the low variability in the patients in relation to the magnitude of the overall deterioration. Measurements of muscle force (myometry and MRC score) had much greater statistical power than measurements of function (motor ability score and walking times) as analyzed by our methods. These observations have important implications for the design of future trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mus.880110807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!